comparing it to the current standard treatment of MSD’s PD-1 inhibitor Keytruda (pembrolizumab) with chemotherapy (cisplatin/carboplatin and pemetrexed). BAY 2927088, which combines inhibition ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
It's been spectacularly successful, but with $17 billion-a-year Keytruda (pembrolizumab) now accounting for more than a third of its total sales there has been pressure on the company to diversify.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback